United Therapeutics (NASDAQ:UTHR) Trading Down 4.4% – Here’s Why

United Therapeutics Co. (NASDAQ:UTHR) shares dropped 4.4% on Wednesday . The company traded as low as $362.70 and last traded at $363.00. Approximately 213,746 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 445,808 shares. The stock had previously closed at $379.69.

Analyst Ratings Changes

UTHR has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH lifted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. HC Wainwright lifted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Jefferies Financial Group lifted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Trading Down 5.8 %

The business’s fifty day moving average is $370.88 and its 200 day moving average is $344.17. The firm has a market capitalization of $15.96 billion, a P/E ratio of 15.70, a P/E/G ratio of 1.05 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the previous year, the business earned $5.38 earnings per share. The firm’s revenue was up 22.9% compared to the same quarter last year. As a group, sell-side analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,792 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $358.62, for a total value of $2,794,367.04. Following the completion of the sale, the chief financial officer now directly owns 4,802 shares of the company’s stock, valued at $1,722,093.24. The trade was a 61.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 119,340 shares of company stock worth $44,765,530. 11.90% of the stock is currently owned by company insiders.

Institutional Trading of United Therapeutics

Several large investors have recently modified their holdings of UTHR. ClariVest Asset Management LLC boosted its holdings in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. Innealta Capital LLC bought a new stake in shares of United Therapeutics during the 2nd quarter worth $33,000. USA Financial Formulas bought a new stake in shares of United Therapeutics during the 3rd quarter worth $33,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics during the 3rd quarter worth $33,000. Finally, Capital Performance Advisors LLP bought a new stake in shares of United Therapeutics during the 3rd quarter worth $82,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.